drugset / Trial / NCT06971744
Autophagy Maintenance (AUTOMAIN)
NaSingle-groupOpen-labelTreatment
Summary
This is a single-institution, single-arm study with a safety lead-in to determine if previously established safe doses of autophagy drugs, hydroxychloroquine (HCQ) and nelfinavir mesylate (NFV) will benefit ovarian cancer patients in a maintenance setting. Patients will receive the two study drugs HCQ and NFV in combination with maintenance bevacizumab.
Timeline
- Start
- 2025-12-18
- Primary completion
- 2028-06-18
- Completion
- 2029-06-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Hydroxychloroquine | Small molecule | 600 mg | Oral |
| Subject | Nelfinavir | Other / unclassified | 1250 mg | Oral |